Back to search

University of Ioannina

Μελέτη της ύπαρξης κυκλοφορούντων νεοπλασματικών κυττάρων και νεοπλασματικών κυττάρων με βλαστικό φαινότυπο και φαινότυπο επιθηλιακής μεσεγχυματικής μετατροπής σε μυελό οστών και περιφερικό αίμα ασθενών με ΚΑΠΕ και συμπαγείς όγκους: συσχέτιση με κλινικοπαθολογοανατομικές παραμέτρους και έκβαση

Abstract

dc:description

About 3% of all cancer patients suffer from Cancer of Unknown Primary Origin(CUP). These patients present with metastatic disease for which a primary site can notbe detected at the time of diagnosis. Sophisticated diagnostic technics and operationalprocedures have failed to improve the diagnostic efficacy in this group of patients.Consequently, it has been adopted today that a policy of a limited diagnostic procedurewith basic laboratory tests and imaging studies is sufficient for the diagnosis of thissyndrome, while the use of immunohistochemistry as well as serum tumor markers ofhigh specificity may help to identify other tumors.What is still missing today is the knowledge of the underling molecular biology ofthese highly metastatic malignancies that are characterized by early aquisition of ametastatic phenotype.Since the exact mechanism of metastases formation has not yet been elucidated,there is a great need for a more extensive study of the metastatic process. Numerousstudies in cancer cell lines and animal models have demonstrated the complexity of themetastatic process. The main stages of metastasis development include the proliferationof cancer cells in the primary site, invasion in surrounding tissues and intravasation intothe circulation, where they can migrate either as single cells or clusters. Afterwards,cancer cells can extravasaste at distant sites and invade new organs to formmicrometastases, where their subsequent proliferation leads to the formation of overtmetastases. These cells, identified either as disseminated tumor cells (DTCs) insecondary sites or as circulating tumor cells (CTCs) in the peripheral blood of patients,consist the population of micrometastatic cells.Several studies have shown that the detection of CTCs in peripheral blood ofpatients with CUP is a strong and independent marker for increased risk of relapse andreduced overall survival. Moreover, the presence of CTCs in breast cancer has beenstrongly correlated with lower response rates to conventional chemotherapies.However, CTCs are a highly heterogeneous population exhibiting differentialmetastatic potential, therefore their further molecular and phenotypic characterizationis of outmost importance. This could highlight those characteristics that prospermetastatic process, contributing to a better understanding of the mechanism ofmetastasis. Moreover, CTCs are considered as a real time liquid biopsy, which allows the molecular characterization of the tumor at different time points. The identificationof CTCs bearing characteristics associated with aggressive behavior or resistance toconventional treatment might also help to identify subgroups of patients with poorprognosis. These patients could be offered more aggressive therapeutic approachesand/or targeted therapies against molecules selected according to their expression onCTCs. Thus, during the last years, a growing number of techniques are being developedfor the detection and characterization of CTCs.Epithelial-to-mesenchymal transition (EMT) of cancer cells is a process holdingan important role in metastasis formation, during which the epithelial phenotypedynamically converts to a mesenchymal one. These mesenchymal characteristicsenable the initial invasion and intravasation of cancer cells, their migration through thesystemic circulation and the subsequent extravasation and invasion at distant sites. Oneof the major changes during EMT is related to the expression pattern of the cytoskeletonintermediate filaments. Specifically, a significant reduction of cytokeratin expressionalong with a simultaneous increase in vimentin expression is usually observed.Moreover, the expression of molecules involved in cell to cell contacts, induced by aseries of transcription factors, such as TWIST, SNAIL and SLUG is also modulated.The expression of the putative EMT markers, Vimentin and TWIST is consideredessential for the invasion and intravasation of cancer cells in the circulation. In addition,numerous studies have shown that characteristics suggestive of the presence of EMT inprimary tumors, are strongly associated with resistance to chemotherapy, high risk ofrelapse and decreased survival.A growing body of evidence suggests a correlation between the EMT process andthe generation of cancer stem cells (CSCs). CSCs have been identified as a smallsubpopulation in several types of cancers, including breast cancer, and are consideredto bear properties of normal stem cells. The CSC model proposes that these cells only,are capable of self-renewal, unlimited proliferation and differentiation, whereas theyhave also been shown to participate in the metastatic process, giving rise to all thesubpopulations that constitute the primary tumor.Based on the above, the detection of putative EMT and CSC markers on CTCscould distinguish a subpopulation of CTCs demonstrating chemoresistance and enhanced metastatic potential. Several studies during the last years have also reportedthe presence of EMT and CSC characteristics on CTCs by the use of differenttechniques, however there are no clinical studies including well defined groups withlarge number of patients. Moreover, the co-expression of CSC and EMT markers at thesingle CTC level has not yet been reported. On this basis, we investigated whetherCTCs of patients with breast cancer, co-express putative stem cell and intermediateEMT phenotypes. Furthermore, we interrogated the frequency of these CTCsubpopulations among patients with early and metastatic disease, evaluated theirpotential prognostic value.For this purpose, a novel triple immunofluorescence methodology was developedon isolated peripheral blood mononuclear cells (PBMCs) of patients, for the detectionof cytokeratins 8, 18 and 19 as a CTC marker, along with ALDH1 and TWIST, asputative CSC and EMT markers, respectively. The co-expression of these moleculeswas evaluated at the single cell level by the use of the semi-automated fluorescencemicroscopy system ARIOL.This study has provided a new, sensitive and specific method for thecharacterization of CTCs according to the co-expression of two putative CSC and EMTmarkers. This study showed for the first time that two putative CSC and EMT markersare frequently co-expressed on single CTCs, reinforcing their association.We further investigated whether CTCs bearing the stem cell phenotype, as definedby the high expression of the isoenzyme ALDH1A1, also acquire functional stem cellcharacteristics. The enzymatic activity of ALDH was used as a functional marker ofCSCs, which was evaluated by ALDEFLUOR assay and the use of flow cytometry.Τhe methodology for the detection of ALDH activity on CTCs was developed througha series of experiments using serial dilutions of tumor cells from each cell line intoisolated PBMCs from normal blood donors (dilutions of 10, 100, 1.000 and 10.000 cellsper 106 PBMCs). Tumor cells were detected by the expression of EpCAM and CD45surface molecules instead of cytokeratin, since the evaluation of intracellular proteinscannot be combined with the ALDEFLUOR assay. CTCs could be identified in all theabove dilutions, however an overestimation of cell counts was observed in lowconcentrations of 10 and 100 tumor cells per 106 PBMCs. ALDH activity could also be detected in all dilutions, however the recovery rate was reduced in low cellconcentrations, suggesting that the developed methodology is appropriate for patientsbearing high CTC counts only.Finally, ALDH enzymatic activity was evaluated on CD45-negative cells, whichinclude the subpopulation of CTCs that have completely lost the expression of epithelialmarkers in the context of full EMT. It was shown that ALDH activity in these cells wasincreased, compared to the population of EpCAM-positive/CD45-negative cells,suggesting that the current approach allows the detection of CTCs bearing a fully EMTphenotype and also functional characteristics of CSCs.Less than 5 CTCs were detected in the blood of 65.2% of a CUP population ofpatients, whereas 14.6% were found with 5 or more CTCs by immunofluorescence. Inaddition to immunofluorescence, flow cytometry was used to determine CTCs. Theanalysis of a separate cohort of patients with CUP, revealed the presence of CTCs in64% of cases. Interestingly enough, in the 28% this population more than 50 CTCswere identified per sample. With respect to clinicopathological features, there was alsono detectable relation between CTCs and age at diagnosis, localization of the disease,patients’ performance status, or leukocytosis in CUP (P>0.05). It was also determinedthe association between CTCs’ detection and survival. The difference in overallsurvival between CTCs <5 and CTCs ≥ 5 groups detected by immunofluorescence wasnot statistically significant, whereas, there was just a weak correlation by flowcytometry (P= 0.049).In addition, a statistically significant association was observed betweenclinicopathological parameters and overall survival in CUP patients. Peritonealcarcinomatosis, well differentiated carcinomas and favorable performance status wereassociated with improved survival.To summarize, this study indicated that CTCs were not related to the poor survivalin CUP patients and no correlation exists between CTCs and other commonclinicopathological parameters. Therefore, CTCs might not be a significantly progressand prognostic indicator for CUP patients. Well-designed clinical studies with largecases of CUP should be performed in the future to validate the relationship betweenCTCs and prognosis of CUP patients. Furthermore, we performed a phenotypic analysis of CTCs from CUP patients, regarding the presence of stem cell and partial EMTcharacteristics. The present study provides a new methodology that allows the sensitiveand specific detection of CSC and EMT markers and their co-expression at the singleCTC level. It was also described for the first time that CSC and EMT markers arefrequently co-expressed on the same CTC, further confirming the correlation betweenthe two states in CTCs. Their prognostic value for patients' survival remains to befurther investigated. The present study highlights the significance of the extensivephenotypic analysis of CTCs for the determination of their role in the metastaticprocess, as well as the need for alternative targeted therapies against moleculesassociated with stem cell and EMT features. This approach could contribute to a moreeffective management of CUP patients.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2016

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Bousios, Stergios
  • Μπούσιος, Στέργιος

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/43888

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Bousios, Stergios; Μπούσιος, Στέργιος. Μελέτη της ύπαρξης κυκλοφορούντων νεοπλασματικών κυττάρων και νεοπλασματικών κυττάρων με βλαστικό φαινότυπο και φαινότυπο επιθηλιακής μεσεγχυματικής μετατροπής σε μυελό οστών και περιφερικό αίμα ασθενών με ΚΑΠΕ και συμπαγείς όγκους: συσχέτιση με κλινικοπαθολογοανατομικές παραμέτρους και έκβαση. University of Ioannina, 2016. http://hdl.handle.net/10442/hedi/43888